Valuation: Alvotech

Market Cap 1.76B 1.58B 1.46B 1.32B 2.47B 168B 2.51B 17.38B 6.93B 87.87B 6.62B 6.48B 278B P/E 2026 *
118x
P/E 2027 * 16.5x
Enterprise Value 2.84B 2.54B 2.35B 2.12B 3.97B 270B 4.03B 27.99B 11.16B 141B 10.65B 10.43B 448B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 3.59x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+2.81%
1 week-7.41%
Current month-18.10%
1 month-22.76%
3 months+53.23%
6 months+34.94%
Current year-7.41%
1 week 4.52
Extreme 4.52
4.97
1 month 4.52
Extreme 4.52
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
7.92
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 57 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 A Free

Chief Executive Officer

117,271 0.0355%
4/1/26 A Sell

Founder

318,000 0.0963%
4/1/26 A Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+2.84%-7.41%-39.64%-47.10% 1.76B
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-1.43%-1.17%+26.27%+55.26% 45.99B
-0.48%-2.80%+18.01%+99.11% 42.45B
+0.82%+1.37%+227.94%+936.89% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.05%+2.70%+43.28%+142.46% 39.43B
Weighted average by Cap. -0.10%+3.08%+49.16%+160.22%

Financials

2026 *2027 *
Net sales 653M 585M 539M 488M 913M 62.15B 927M 6.43B 2.57B 32.53B 2.45B 2.4B 103B 786M 704M 649M 588M 1.1B 74.84B 1.12B 7.75B 3.09B 39.17B 2.95B 2.89B 124B
Net income 2.25M 2.01M 1.86M 1.68M 3.14M 214M 3.19M 22.14M 8.83M 112M 8.43M 8.25M 355M 80.1M 71.74M 66.19M 59.9M 112M 7.63B 114M 790M 315M 3.99B 301M 294M 12.64B
Net Debt 1.08B 963M 889M 804M 1.5B 102B 1.53B 10.6B 4.23B 53.6B 4.04B 3.95B 170B 1.06B 946M 873M 790M 1.48B 101B 1.5B 10.41B 4.15B 52.62B 3.96B 3.88B 167B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
27/10/26 $4.750 +2.81% 733,474
28/10/26 $4.940 +4.00% 627,918
27/10/26 $4.750 +2.81% 733,474
26/10/26 $4.620 +0.87% 584,889
23/10/26 $4.580 -4.38% 666,200
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.940USD
Average target price
7.200USD
Spread / Average Target
+45.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock